Cargando…
Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial
Patients with stroke or transient ischemic attacks (TIAs) and internal carotid artery stenosis harbor an increased risk of recurrent stroke especially within 2 weeks after the first event. In addition, the revascularization procedure itself (carotid endarterectomy [CEA] or carotid artery stenting [C...
Autores principales: | Gröschel, Klaus, Uphaus, Timo, Loftus, Ian, Poppert, Holger, Diener, Hans Christoph, Zobel, Jenny, Münch, Götz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704244/ https://www.ncbi.nlm.nih.gov/pubmed/33274312 http://dx.doi.org/10.1055/s-0040-1721078 |
Ejemplares similares
-
Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke
por: Reimann, Andreas, et al.
Publicado: (2016) -
The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
por: Goebel, Silvia, et al.
Publicado: (2013) -
The antiplatelet agent revacept prevents the increase of systemic thromboxane A(2) biosynthesis and neointima hyperplasia
por: Alberti, Sara, et al.
Publicado: (2020) -
The GPVI – Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding Times
por: Ungerer, Martin, et al.
Publicado: (2013) -
Factors associated with time delay to carotid stenting in patients with a symptomatic carotid artery stenosis
por: Gröschel, Klaus, et al.
Publicado: (2011)